Although the market remained on the rise, 2011 marked a slowdown against the preceding years, when the drug industry grew by 15-20%.
The weaker growth can be put down to precaution, as companies are refunded by the state for free and subsidized drugs after as much as one year, according to information previously supplied by the companies.
The decline in purchasing power also affected sales of over-the-counter drugs. They rose 4.9% in euro terms in the first seven months of the year, below the market.
Medicine for heart conditions generates over EUR280 million in cumulated sales, up 3.8% in euro terms. This category has been the best-seller for several years. Heart conditions are the main cause of death in Romania.
On the other hand, the best-selling drug in Romania (by value) in the first seven months of the year was Seretide (used in the treatment of respiratory conditions, part of the GSK portfolio). Seretide posted EUR24 million in sales in the first seven months, around EUR4 million ahead of the second-best seller, MabThera (used in the treatment of cancer, part of the Roche portfolio).
The leader of the drug market was Sanofi-Aventis, with EUR128 million in sales in the first seven months of the year. No. 2 is Roche, close behind, with sales of around EUR121.5 million. At no. 3 is GlaxoSmithKline, with EUR96.2 million in sales.
(English version by Daniela Stoican; Editing by Radu Bostan)